TreeFrog Therapeutics

📍 Pessac, France🗓 Founded 2018👥 160 employees💰 Last funded Nov 2024
Biotechnology Research🌐 treefrog.fr
Website LinkedIn
TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 150 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M in 2021 to advance its pipeline of stem cell-based therapies in the field of regenerative medicine with the lead program in Parkinsons Disease. In 2022, the company opened a technological hub in Boston, USA to drive the adoption of C-Stem and initiate co-development partnerships with leading academic, biotech and industry players in the field of cell therapy.
4
Total investors
2
Early stage
1
Mid stage
1
Late stage
2018
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
4
Investor activity2019–2024 · investors recorded per year
20191202012023120241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in TreeFrog Therapeutics?
TreeFrog Therapeutics has 4 investors on record on gritt.io, including 2 early-stage backers, 1 mid-stage and 1 late-stage investors.
When did TreeFrog Therapeutics last raise funding?
The most recent investment in TreeFrog Therapeutics recorded on gritt.io was in November 2024.
When was TreeFrog Therapeutics founded?
TreeFrog Therapeutics was founded in 2018.
What industry is TreeFrog Therapeutics in?
TreeFrog Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is TreeFrog Therapeutics based?
TreeFrog Therapeutics is headquartered in Pessac, France.